MS
PHAS

Maven Securities’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Maven Securities’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-75,000
Closed -$253K – 1468
2021
Q1 		$253K Buy
+75,000
New +$304K 0.01% 855

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Maven Securities's PHAS Position: Q2 2021 in Review

Maven Securities sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 75,000 shares — an estimated $253K sold.

Maven Securities first reported a position in PHAS in Q1 2021 and held it in 1 quarter. The position peaked at $253K in Q1 2021. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

  • Maven Securities reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 75,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $253K.
  • Maven Securities first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Maven Securities's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $253K in Q1 2021.
  • 55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.